Senate Bill 61: Cap cost sharing for prescription insulin drugs

Primary Sponsor

Senator Hearcel F. Craig (D)

Primary Sponsor

Senator Nathan H. Manning (R)

SB 61 prohibits a health plan issuer from imposing – on a prescription insulin drug – cost sharing in an amount that exceeds $35 for a 30-day supply. The prohibition applies as follows: (1) only to health plan issuers that provide coverage for prescription insulin drugs and (2) regardless of the amount or type of insulin needed to fill a covered person’s prescription. Under the bill, cost sharing must be charged on a per-prescription-fill basis.

• Legislation Status

  The Health Committee held its first hearing on the bill in March 2023.

• Legislation Text

  Read the contents of the legislation, as introduced, here.

• Legislation Testimony

  Read the testimony from the hearing here.